Rheumatology Network's Top 5: July 16, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 16, 2021.
Autoimmune Rheumatic Disease Does Not Influence Immune Response Against COVID-19
Research indicates that patients with autoimmune rheumatic diseases (AIRD) did not differ from the general population in terms of protective antibody responses against COVID-19.
Click the image to view the story.
Tofacitinib and Adalimumab Significantly Improved Pain for Patients With Psoriatic Arthritis
“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.
Click the image to view the story.
Overdrive Podcast: Value-Based Care in Rheumatology
On the latest episode of Overdrive, we sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Click the image to view the story.
Q&A: Clinical, Molecular Associations With Knee Injury Outcomes
In this Q&A, corresponding author, Fiona Watt, MBBS, PhD, FRCP, discusses her study that found the combination of effusion and hemarthrosis at the time of acute knee injury is associated with adverse outcomes at 2 years post-injury.
Click the image to view the story.
Erectile Dysfunction Decreases Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis
Surprisingly, patients with rheumatoid arthritis and erectile dysfunction had a significantly decreased rate of myocardial infarction, heart failure, and death when compared with patients with rheumatoid arthritis alone.
Click the image to view the story.
